|
|
MTH-68/H oncolytic viral treatment in human
high-grade gliomas
L.K. Csatary, G.
Gosztonyi, J. Szeberenyi, Z. Fabian, V. Liszka, B. Bodey and C.M. Csatary
United Cancer Research
Institute, Alexandria, VA, USA (L.K.C., V.L., C.M.C.); Department of
Neuropathology, University Clinics Benjamin
Franklin, Freie Universitaet Berlin, Berlin, Germany (G.G.); Department of Medical
Biology, School of Medicine, University of Pécs, Pécs, Hungary (J.S., Z.F.);
Department of Pathology, Keck School of
Medicine, University of Southern California (B.B.); Children’s Center for Cancer
and Blood Diseases, Children’s Hospital, Los Angeles, CA, USA (B.B.). UCRI@aol.com
Application of virus therapy to treat human neoplasms has over a three decade
history.
MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease
virus, is one of the viruses used in the treatment of different
malignancies.
Here we report on the administration of MTH-68/H to patients with glioblastoma
multiforme, the most common and most aggressive neuroectodermal neoplasm with a
poor prognosis, averaging six months to a year.
Four cases of advanced high-grade glioma were treated with MTH-68/H after the
conventional modalities of anti-neoplastic therapies had failed.
This treatment resulted in survival rates of 5-9 years, with each patient still
living today.
Against all odds, each patient resumed a lifestyle that resembles their previous
daily routines and enjoys a good quality of life, Each of these patients has
regularly received MTH-68/H as their sole form of onco-therapy for a number of
years now without interruption.
PMID: 15072452 [PubMed]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15072452
|
